不同年龄对阿替普酶静脉溶栓治疗急性脑梗死的临床疗效和预后的影响

发布时间：2019-03-22 08:18

【摘要】：目的评价不同年龄对阿替普酶静脉溶栓治疗急性脑梗死的临床疗效和预后的影响。方法将98例脑梗死患者按年龄分为高龄组52例和低龄组46例。2组患者均予以0.9 mg·kg-1阿替普酶静脉溶栓治疗。比较2组患者溶栓前和溶栓后1,21 d的临床疗效,美国国立卫生研究院卒中量表(NIHSS)评分以及不良反应发生情况,并于3周后进行改良Rankin量表(mRS)评分。结果治疗后,2组患者的NIHSS评分均明显低于治疗前(P0.05)。治疗后1,21 d,低龄组的NIHSS评分明显低于高龄组(P0.05)。治疗后,低龄组的不良反应发生率明显低于高龄组(P0.05)。治疗3周后mRS评分表明,低龄组的预后明显优于高龄组(P0.05)。结论阿替普酶静脉溶栓治疗急性脑梗死,2组患者均可以从治疗中获益,但低龄组的溶栓效果明显优于高龄组,且并发症较少,预后相对较好。
[Abstract]:Objective to evaluate the effect of different age on the clinical efficacy and prognosis of patients with acute cerebral infarction treated by intravenous thrombolytic therapy with ateptidase. Methods 98 patients with cerebral infarction were divided into elderly group (n = 52) and low age group (n = 46) according to their age. All patients in both groups were treated by intravenous thrombolytic therapy of 0.9 mg kg-1 atteppase. The clinical efficacy, (NIHSS) score and side effects of NIH Stroke scale were compared before thrombolysis and 1, 21 days after thrombolysis. The (mRS) score of modified Rankin scale was performed 3 weeks later. Results after treatment, the NIHSS scores of the two groups were significantly lower than those before treatment (P0.05). On the 1st and 21st day after treatment, the NIHSS score of the low age group was significantly lower than that of the high age group (P0.05). After treatment, the incidence of adverse reactions in the low age group was significantly lower than that in the high age group (P0.05). After 3 weeks of treatment, mRS scores showed that the prognosis of the low age group was significantly better than that of the high age group (P0.05). Conclusion intravenous thrombolytic therapy with ateptidase can benefit both patients from acute cerebral infarction, but the thrombolytic effect of the low age group is obviously better than that of the elderly group, and the complications are less and the prognosis is relatively good.
【作者单位】：宁波鄞州第二医院神内科;宁波鄞州第二医院心血管内科;台州市中心医院神经内科;宁波余姚市人民医院神经内科;
【分类号】：R743.33

【相似文献】